Action 6628 TRANSCENTA HOLDING LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Transcenta Holding Limited

Actions

6628

KYG9005B1041

Temps Différé Hong Kong S.E.
Autres places de cotation
 10:08:14 11/06/2024 		Varia. 5j. Varia. 1 janv.
1,66 HKD 0,00 % Graphique intraday de Transcenta Holding Limited -5,68 % -53,76 %
07/06 Transcenta Holding Limited (SEHK:6628) lance un plan de rachat d'actions pour 43.637.537 actions, représentant 10% de son capital social émis, dans le cadre de l'autorisation approuvée le 7 juin 2024. CI
07/06 Transcenta Holding Limited annonce des changements au sein de sa direction et de son conseil d'administration CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Transcenta Holding Limited commences an Equity Buyback Plan for 43,637,537 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.
Transcenta Holding Limited Announces Directorate and Board Changes
Transcenta Holding Limited's Equity Buyback announced on June 9, 2023, has expired.
Transcenta Shows 'Encouraging' Data from Gastric Cancer Combination Drug Trial
Transcenta Holding Limited Announces Updates of Phase II Data from First-Line Triple Combination Trial of Osemitamab for G/GEJ Cancer at ASCO 2024
Transcenta Holding Limited Announces Board and Nomination Changes
Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic
Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial
Transcenta Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Transcenta Publishes Promising Results of Anti-Tumor Drug's Efficacy and Safety in European Journal
Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
Transcenta Presents Data on Gastric/Gastroesophageal Cancer Treatment Trial at Spain Oncology Meet
Transcenta Holding Limited Presents Updated Efficacy Data from the Expansion Cohort of the Transtar102 of Osemitamab Plus Capox Chemotherapy Study as the First-Line Treatment of Advanced G/Gej Cancer At the ESMO Congress 2023 in Madrid, Spain
US FDA Approves Phase 3 Trial for Transcenta's Gastric Cancer Treatment
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Transcenta Widens Loss in H1
Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023
Transcenta Holding Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Transcenta Moves to Phase II Trial of Osteoporosis Drug
Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 6628
  4. Actualités Transcenta Holding Limited
  5. Autres langues